Stada Arzneimittel AG - Company Profile
Powered by 
All the sales intelligence you need on Stada Arzneimittel AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Stada Arzneimittel AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Stada Arzneimittel AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Stada Arzneimittel AG, a subsidiary of Nidda Healthcare GmbH (Stada), is a producer of consumer healthcare, generics, and specialty pharmaceutical products. Its major products include medicines for cough and cold, dermatology, pain and relief, vitamins, minerals, gastric issues, sleep, women's and men's health, bone health, immunology, nephrology, neurology, oncology, ophthalmology, and biosimilars. The company also distributes products of other pharmaceutical companies. It offers products to a wide range of customers and patients through brands such as Nizoral, Zoflora, Grippostad, SNUP, Silomat, and Hirudoid, among others, in Asia, the Middle East, and Europe. Stada is headquartered in Bad Vilbel, Hessen, Germany.
Headquarters
Germany
Address
Stadastrasse 2-18, Bad Vilbel, Hessen, 61118
Website
www.stada.com
Telephone
49 610 16030
No of Employees
11,649
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$4.4B
Stada Arzneimittel AG premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Consumer Health: | Zoflora |
| - Cough and Cold: | Snup |
| - Nasal Decongestant | Nizoral |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In June, the company acquired 16 vitamins, minerals and supplements (VMS) products from Orifarm. |
| 2026 | Asset Purchase | In May, the company acquired certain rights to the Locobase Dermatology brand from Karo Healthcare, a pharma company. |
| 2026 | Stake Sale | In March, the company sold its majority stake held by Bain Capital and Cinven to CapVest Partners LLP. |
Competitor Comparison
| Key Parameters | Stada Arzneimittel AG | Sanofi | Bayer AG | Reckitt Benckiser Group Plc | Teva Pharmaceutical Industries Ltd |
|---|---|---|---|---|---|
| Headquarters | Germany | France | Germany | United Kingdom | Israel |
| City | Bad Vilbel | Paris | Leverkusen | Slough | Tel Aviv |
| State/Province | Hessen | Ile-de-France | Nordrhein-Westfalen | Berkshire | Tel Aviv |
| No. of Employees | 11,649 | 76,493 | 87,757 | 36,000 | 31,173 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gunter von Au | Chairman | Executive Board | 2017 | 75 |
| Peter Goldschmidt | Chief Executive Officer | Senior Management | 2018 | - |
| Boris Dobler | Chief Financial Officer | Senior Management | 2023 | - |
| Simone Berger | Chief Human Resources Officer | Senior Management | 2021 | - |
| Miguel Pagan Fernandez | Chief Technical Officer | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer